An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Condition: Breast Cancer, Early Breast Cancer Interventions: Drug: Camizestrant; Drug: Tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Abemaciclib Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Study | Tamoxifen